Three major effects
”API specific biological therapy has the functions of detoxification of heat, killing cancer cells, activating blood circulation and stasis, softening and dispersing knots, removing phlegm and dampness, etc. After treatment, the tumor will become soft, shrink and finally disappear.
(1) Eliminate hydrocele – If cancer cells invade meninges, pleura or peritoneum, hydrocephalus, pleural fluid or ascites will be formed easily.
(2) Eliminate the cancer tumor – that is, eliminate the tumor body. After one course of treatment, the tumor can be softened and shrunken, and the pressure symptoms can be reduced; after three courses of treatment, the tumor will be obviously shrunken in most patients, and in some patients the tumor will disappear.
(3) Eliminate cancer pain – When cancer reaches advanced stage, or after metastasis or proliferation, it is easy to have pain symptoms, and some of them are even severe pain. Anti-cancer herbal medicine has good analgesic effect, and some patients can see the effect in short term. It is highly effective and thorough because it stops pain on the basis of killing cancer cells and eliminating tumor.
Combination therapy
Biological therapy + surgery
It improves the patient’s pre-surgical resistance, quickly recovers the immune damage caused by surgery, removes the residual tumor cells and micro lesions after surgery, and prevents metastasis and recurrence.
Biological therapy + radiotherapy
Radiotherapy plus multicellular therapy enhances the sensitivity of radiotherapy, improves the tolerance of radiotherapy, reduces the toxic side effects of radiotherapy, and is safer for patients.
Biotherapy + Chemotherapy
Increase the sensitivity of chemotherapy, reduce the side effects of chemotherapy drugs and immunosuppression, enhance drug resistance and immunity, and remove the dormant tumor cells that have not been killed.
Biological therapy + Chinese medicine treatment
Combining with biological therapy can remove cancer cells from the source, improve the therapeutic effect and achieve survival with tumor.
The Chinese medicine ginsenoside Rh2 can act on proliferating tumor cells, especially the more sensitive S and M phases, so that cancer cells cannot make DNA replication and reduce cancer cells to enter the next division cycle, thus inhibiting cancer cell proliferation, shrinking tumors, controlling the disease and improving patients’ quality of life. Combined with biological immunotherapy, they complement each other to achieve better treatment effect.
Contraindications
(1) Pregnant women or women who are breastfeeding;
(2) Patients with T-cell lymphoma;
(3) Patients with severe uncontrollable infections;
(4) Patients who are allergic to biological products such as IL-2;
(5) Patients with AIDS;
(6) Patients who are undergoing systemic radiotherapy or chemotherapy;
(7) Patients with cachexia and low peripheral blood count caused by advanced tumors
(8) Patients with organ failure
Heart: grade IV or above; Liver: domestic liver function classification grade C or above;
Kidney: renal failure and uremia;
Lung: severe respiratory failure symptoms and involvement of other organs, such as liver and kidney function;
Commonly used cells
Cytokine-induced killer cells are an effective immunologically active cell for killing. Under in vitro conditions, human peripheral blood mononuclear cells (PBMC) are induced to become a population of heterogeneous cells after co-stimulation by multiple cytokines, which have the advantages of rapid proliferation, high tumoricidal activity and low toxicity to normal bone marrow hematopoiesis.
It is believed that the tumor killing effect of CIK cells is achieved by the following three mechanisms: lysis of target cells through the release of granzyme and perforin, which is the main mechanism for CIK cells to kill target tumor cells; in vivo activated CIK cells can secrete a variety of cytokines such as interferon γ, tumor necrosis factor and interleukin 2, which not only have a direct inhibitory effect on tumor cells, but also through the regulation of immune system to kill tumor cells indirectly; CIK cells expressing FasL (type II transmembrane glycoprotein) induce tumor cell apoptosis by binding to tumor cell membrane-expressed Fas (type I transmembrane glycoprotein).
DC cells
DC cells are Dendritic Cells, which are the most powerful antigen-presenting cells known in vivo. After in vitro expansion and sensitization of tumor antigens, DC cells are transfused back to patients, which can induce T cells to proliferate and differentiate into cytotoxic T cells and activate B lymphocytes, and activate the antibody immune system to produce efficient and specific anti-tumor effects. Due to the low content of DCs in vivo, it is difficult to meet the needs of clinical application, so obtaining a large number of mature DCs is the basis of clinical application.
DC-CIK
DC-CIK is a combination of two types of cells, dendritic cells (DC cells) and cytokine-induced killer cells (CIK cells), which can not only stimulate and enhance the specific anti-tumor immune response of tumor patients, but also prevent the recurrence of tumor foci after conventional treatments (surgery, chemotherapy and radiotherapy).
Tumor cell “radar”
Dendritic cells (DCs) are the most powerful antigen-presenting cells known in the body, capable of stimulating the proliferation and activation of initial T cells, recognizing tumor cells, inhibiting tumor angiogenesis, and stimulating immune memory protection. This cell is like a “radar” that can actively search and identify tumor cells in the body along with blood throughout the body, and transmit the information to immune activated cells to promote their activation and massive proliferation.
DC cell regeneration therapy means that DC cells are successfully cultured by collecting peripheral blood, using special cell isolation solution, extracting and purifying, and then injecting the cells into the patient’s body through targeted targeting and intravenous infusion. The cells can rapidly proliferate and differentiate into hepatocytes under the regulation of liver microenvironment, repair damaged hepatocytes and restore the regenerative ability of necrotic hepatocytes; and trigger a series of immune response through blood flow, rebuild the function of patient’s immune system, produce a large number of specific lymphocytes with immunocidal effect, and carry out precise, specific and It can kill the hepatitis virus in the body thoroughly and effectively, so that the diseased hepatocytes in the patient’s body can be purified and the “living environment” of the hepatocytes can be purified, so that the liver cancer can be effectively controlled and the liver function can be completely restored, thus realizing the truly individualized treatment. Thus, the purpose of effective treatment of liver cancer can be achieved.
CIK cells – a “precision missile” to kill tumor cells
Cytokine-induced killer cells (CIK) are a heterogeneous group of cells obtained by co-culturing human peripheral blood single nucleus cells with various cytokines in vitro, which have the advantages of strong anti-tumor activity and non-restricted tumor killing and can be used for any stage of tumor patients.
CIK cell immunotherapy requires both sufficient cell numbers and high cell viability, as the CD3+CD56+ effector cells in normal human peripheral blood are low, accounting for only 1-5%, and even lower in tumor patients.
The cells have a strong ability to accurately identify and kill tumor cells (without damaging normal cells), and are especially effective in treating patients after surgery or radiotherapy, eliminating small metastatic lesions, preventing the spread of tumor cells and recurrence, and improving the immunity of the body.
API-specific combined application achieves efficacy 1+1 > 2
DC and CIK cells have complementary effects in anti-tumor cells, and their combined application can achieve the efficacy of “1+1 > 2”. It is also a great comfort to the patient’s family.
1.A certain amount of peripheral blood was collected with a blood cell separator.
2. In the gmp lab, single nucleated cells are isolated and placed in culture flasks, and culture medium and cytokines are added to stimulate the cells to activate and increase their value.
3.After 7-14 days of cell culture, the cell number increases to hundreds to thousands of times of the original number, and the immunocidal ability increases 20-100 times.
4.On the 7th-14th day after blood collection, the transfusion of dc and cik cells will be started.
5.After several courses of treatment, it can effectively kill tumor cells, promote patient’s recovery and improve patient’s quality of life.
Development history
In 1992, the U.S. FDA officially passed the issue of considering biological immunotherapy as one of the basic cancer therapies, and the therapy was widely used in the U.S. clinic.
In 2000, Dr. Yamazaki et al. reported the clinical trial results of bioimmunotherapy for liver cancer in The Lancet, and the results showed that the technology could effectively prevent the metastasis and recurrence of tumors.
In March 2009, the Ministry of Health of China promulgated the Measures for the Administration of Clinical Application of Medical Technology, which included “autoimmune cell therapy technology” into the third category of technology for management, and medical institutions that passed the approval could carry out clinical application.
In April 2011, CCTV News reported on CLS bio-immunotherapy technology, pointing out that bio-immunotherapy has made a key breakthrough in treating tumors, and one third of early cancers can be cured.
In October 2011, French scientist Ralph Steinman was awarded the Nobel Prize in Medicine for “the discovery of dendritic cells and their role in acquired immunity”, marking that bioimmunotherapy has become a novel therapy for cancer treatment.
On March 6, 2012, the Chinese Ministry of Health formally included bioimmunotherapy for cancer treatment in its technical management approach.
On April 15, 2012, the Chinese government officially included the therapeutic technology biological cell immunity into the medical insurance, marking the formal entry of biological immunotherapy into the domestic medical insurance system.